Compounds > hydroxyflutamide
Page last updated: 2024-08-26

hydroxyflutamide and Adenocarcinoma

hydroxyflutamide has been researched along with Adenocarcinoma in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (42.86)18.2507
2000's4 (57.14)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Stöckle, M; Tahmatzopoulos, A; Unteregger, G; Wullich, B; Zwergel, T; Zwergel, U1
Chang, CY; Elbi, C; Hager, GL; Hendarwanto, A; Klokk, TI; Kurys, P; Nagaich, AK; Saatcioglu, F; Slagsvold, T1
Charreau, EH; Dran, G; Lanari, C; Luthy, IA; Molinolo, AA; Montecchia, F; Pasqualini, CD1
Berrevoets, CA; Mulder, E; Veldscholte, J1
Gurpide, E; Markiewicz, L1
Bentel, JM; Buchanan, G; Greenberg, NM; Han, G; Harris, JM; Horsfall, DJ; Marshall, VR; Matusik, RJ; Moore, N; Nahm, HS; Tilley, WD; Yang, M1
Appa Rao, KB; Gui, Y; Lessey, BA; Lovely, LP1

Other Studies

7 other study(ies) available for hydroxyflutamide and Adenocarcinoma

ArticleYear
Proteasome inhibitors and their combination with antiandrogens: effects on apoptosis, cellular proliferation and viability of prostatic adenocarcinoma cell cultures.
    Prostate cancer and prostatic diseases, 2004, Volume: 7, Issue:2

    Topics: Adenocarcinoma; Androgen Antagonists; Apoptosis; Cell Division; Cell Survival; Cysteine Proteinase Inhibitors; Drug Interactions; Flutamide; Humans; Leupeptins; Male; Oligopeptides; Prostatic Neoplasms; Protease Inhibitors; Tumor Cells, Cultured

2004
Ligand-specific dynamics of the androgen receptor at its response element in living cells.
    Molecular and cellular biology, 2007, Volume: 27, Issue:5

    Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Anilides; Animals; Cell Line, Tumor; Chromatin Assembly and Disassembly; Cyproterone Acetate; Dihydrotestosterone; Female; Fluorescence Recovery After Photobleaching; Flutamide; Genes, Reporter; Green Fluorescent Proteins; In Situ Hybridization, Fluorescence; Ligands; Luciferases; Mammary Neoplasms, Animal; Mammary Tumor Virus, Mouse; Metribolone; Mice; Microscopy, Video; Mifepristone; Models, Biological; Nitriles; Plasmids; Promoter Regions, Genetic; Receptors, Androgen; Response Elements; Testosterone; Tosyl Compounds; Transcription, Genetic

2007
Effect of medroxyprogesterone acetate (MPA) and serum factors on cell proliferation in primary cultures of an MPA-induced mammary adenocarcinoma.
    Breast cancer research and treatment, 1995, Volume: 35, Issue:2

    Topics: Adenocarcinoma; Androgen Antagonists; Animals; Blood Physiological Phenomena; Cell Division; Dexamethasone; Dihydrotestosterone; Estradiol; Female; Flutamide; Mammary Neoplasms, Experimental; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Mifepristone; Ovariectomy; Progesterone; Tumor Cells, Cultured

1995
Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
    The Journal of steroid biochemistry and molecular biology, 1993, Volume: 46, Issue:6

    Topics: Adenocarcinoma; Alanine; Amino Acid Sequence; Androgen Antagonists; Anilides; Animals; Blotting, Western; Cell Line; Cell Nucleus; Chloramphenicol O-Acetyltransferase; Cyproterone Acetate; Dose-Response Relationship, Drug; Flutamide; Humans; Male; Metribolone; Mutagenesis, Site-Directed; Nitriles; Point Mutation; Prostatic Neoplasms; Receptors, Androgen; Recombinant Proteins; Threonine; Tosyl Compounds; Transcription, Genetic; Transfection; Transformation, Genetic; Tumor Cells, Cultured

1993
Estrogenic and progestagenic activities of physiologic and synthetic androgens, as measured by in vitro bioassays.
    Methods and findings in experimental and clinical pharmacology, 1997, Volume: 19, Issue:4

    Topics: Adenocarcinoma; Alkaline Phosphatase; Androgen Antagonists; Androgens; Breast Neoplasms; Cyproterone Acetate; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Flutamide; Gonanes; Humans; Mifepristone; Polyunsaturated Alkamides; Progestins; Tamoxifen; Testosterone; Testosterone Congeners; Tumor Cells, Cultured

1997
Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.
    Molecular endocrinology (Baltimore, Md.), 2001, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Animals; Binding Sites; Cell Line; COS Cells; Dihydrotestosterone; DNA; Estradiol; Flutamide; Humans; Male; Mice; Mice, Transgenic; Models, Molecular; Mutagenesis; Mutation; Progesterone; Prostatic Neoplasms; Protein Structure, Secondary; Receptors, Androgen; Structure-Activity Relationship; Transcriptional Activation; Transfection

2001
Characterization of androgen receptors in a well-differentiated endometrial adenocarcinoma cell line (Ishikawa).
    The Journal of steroid biochemistry and molecular biology, 2000, Nov-15, Volume: 74, Issue:4

    Topics: Adenocarcinoma; Alkaline Phosphatase; Androgens; Cell Differentiation; Cell Nucleus; Diethylstilbestrol; Dihydrotestosterone; Endometrial Neoplasms; Endometrium; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Flutamide; Fulvestrant; Humans; Metribolone; Progesterone; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured

2000